期刊
CANCERS
卷 8, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/cancers8110103
关键词
AXL; GAS6; metastasis; cancer stem cell phenotype; immune suppression; therapy; proliferation; resistance; small molecule; decoy receptor
类别
资金
- NIH [CA-198291, CA-67166, CA-197713]
- Silicon Valley Foundation
- Sydney Frank Foundation
- Kimmelman Fund
- Department of Defense Ovarian Cancer Research Program [W81XWH-15-1-0097]
The AXL receptor tyrosine kinase (AXL) has emerged as a promising therapeutic target for cancer therapy. Recent studies have revealed a central role of AXL signaling in tumor proliferation, survival, stem cell phenotype, metastasis, and resistance to cancer therapy. Moreover, AXL is expressed within cellular components of the tumor microenvironment where AXL signaling contributes to the immunosuppressive and protumorigenic phenotypes. A variety of AXL inhibitors have been developed and are efficacious in preclinical studies. These agents offer new opportunities for therapeutic intervention in the prevention and treatment of advanced disease. Here we review the literature that has illuminated the cellular and molecular mechanisms by which AXL signaling promotes tumor progression and we will discuss the therapeutic potential of AXL inhibition for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据